

Innovation Department

TECNIO Facilitador

Institut de Recerca Biomèdica de Barcelona (IRBB)



ACCIÓ

Generalitat de Catalunya

tecnio
catalonia



The Research Institutes, based on the research activity, generate knowledge and some results that can be taken advantage of by the companies. The TECNIO Facilitador puts you in touch with the spin-offs, the technologies in the licensing phase and the technological capacities of the Research Group.

IRB Barcelona is an independent, non-profit research centre engaged in basic and applied biomedical science that is home to nearly 400 research, technical and support staff from 35 countries. It was created by the Government of Catalonia and the University of Barcelona in October 2005. IRB Barcelona is part of the Barcelona Institute of Science and Technology (BIST).

IRB Barcelona's missions include conducting multidisciplinary research of excellence at the unique interface between biology, chemistry and structural/computational biology, providing high-level training in the biomedical sciences to staff, students and visitors, driving innovation through active technology transfer to the benefit of society, and actively participating in an open dialogue with the public through a series of engagement and education activities.

TECHNOLOGY PORTFOLIO

Technologies. Current portfolio includes 13 technologies available for licensing and all of them distributed in industrial sectors: Biotechnology (9) and ICT (3).

Spin-offs. Up to date, IRB Barcelona has set up 4 spin-off companies: Nostrum Biodiscovery, Inbiomotion, Iproteos and Omnia Molecular. All of them belong to the application of Health industry (4).

MOST RELEVANT PROJECTS

In 2012, the Innovation Department has set up **BiomedTec**, an internal **accelerator programme**. It is focused on funding key experiments for potential transferrable early-stage technologies/projects, adding value or validating them, thus strengthening the application to Proof of Concept calls. So far, 5 calls have been placed and supported 12 different projects.

Licenses. License of a new technology related to molecules of pharmaceutical interest to a national company from the **chemistry-biotech sector**.

EBT's. In 2016, two of our spin-offs, Iproteos and Inbiomotion, closed investment rounds of **1.2** and **2.2M€**, respectively. Iproteos is a biotech drug developing company based on protein-protein interaction disruption for CNS disorders. Inbiomotion is a personalized medicine company developing biomarkers that predict bone metastasis.

SOME AVAILABLE TECHNOLOGIES



3
ICT

- New web-server to predict the relevance of specific genetic mutations to the outcome of cancer treatments.



9
Biotechnology

- Platform of BBB-peptide shuttles for drug delivery.
- A novel target in Alzheimer's disease. -Tool to provide oncoselectivity to viral therapy.

APPLICATION SECTORS OF THE AVAILABLE TECHNOLOGIES



Chemistry, energy and resources. Organic chemistry.



Health and life sciences. Hospital and associated foundations. University groups, science and technology parks, research centres. Fine chemicals.



Address

Baldiri Reixac, 10
08028 Barcelona Barcelonès

Contact person

Cristina Horcajada
innovation@irbbarcelona.org
0034934020250

Director

Joan J. Guinovart

Surface incubation spaces in m2

0

Staff

4

www.irbbarcelona.org